Spryng for Canine and Feline

Administration

1. Vigorously flick and agitate the syringe to dislodge and disperse the particles homogeneously.

2. Insert a sterile needle (19-25g for horses or 22-25g for dogs and cats) into the joint space.

3. At the veterinarians discretion, inflammatory synovial fluid may be aspirated and discarded using a separate syringe while the needle remains in place.

4. Verify that the Spryng material is evenly dispersed within the syringe.

5. Attach the Spryng luer-lock syringe to the still-inserted needle.

6. Apply even pressure on the plunger while injecting.

7. Do not over-distend joints.

8. If additional product is needed, detach the empty syringe, then repeat the procedure with a new syringe maintaining aseptic technique.

9. When completed, remove the needle and syringe from the joint space and discard appropriately.

10. If a syringe is only partially used, discard the unused portion. Syringes are for single use only.

Equine Knee Injection

Canine Elbow Injection

Additional Administration Information

● Inflammation should be controlled prior to administration.

● Treatment with anti-inflammatory medications for at least five days pre-injection and ten days post-injection may improve medical outcomes and reduce the risk of adverse reactions.

● The optimal injection technique, location, and volume of Spryng administered may vary depending on the specific joint, patient, and the veterinarians clinical assessment.

● Multiple joints may be injected as a part of the same procedure.

● Improvement may be seen as early as 48 hours post-injection, but full benefits can take up to three weeks.

● Repeat or additional administration of Spryng may be considered based on the veterinarian’s assessment.

● Field experience suggests the benefits are long lasting and may extend beyond one year.

● A maximum annual administration frequency has not been established.

Risks and Side Effects

In field experience, less than 1% of animals experience adverse effects.

Animals may be uncomfortable within the first 48 hours of injection, similar to other intra-articular products.

Some animals may experience temporary swelling and discomfort in the injected joint beginning 7 to 14 days after injection, coinciding with the integration of the Spryng bioscaffold into the subsynovial tissue.

Veterinarians should use their clinical judgment to determine whether unexpected signs suggest a potentially septic joint.

If not septic in origin, these events normally resolve with prompt treatment with FDA-approved anti-inflammatory medications and rest.

Counseling for Owners

Discuss with owners the expected outcomes, including time to onset, duration, and level of improvement before administering Spryng.

Review contraindications, precautions, and potential complications. For optimal results, pre- and post-administration NSAIDs, strict stall/cage rest for 48 hours, and a gradual return to activity over two weeks should be followed.

Owners should be encouraged to contact their veterinarian immediately if unexpected signs occur.

Detailed guidance can be found in the Spryng Administration Guidelines and Best Practices on our Veterinarian Resources Page.

Potential Adverse Reactions

Adverse events should be promptly reported to PetVivo at 844-PET-VIVO (7388486) or info1@PetVivo.com

*Veterinarian Resources

For additional information, including FAQs, Administration Guidelines and Best Practices, Injection Volume Guidelines, safety data and case studies, visit: www.sprynghealth.com

Storage

Spryng should be stored at room temperature with a range of 40° - 90°F (5°-30°C). Use within the expiration date stated on the package.

Disposal

The syringe and any unused material must be discarded after a single treatment visit. Follow national, local, or institutional guidelines for use and disposal of medical sharp devices.

MADE IN THE USA

Manufactured by PetVivo, Inc. 5251 Edina Industrial Blvd, Minneapolis, MN 55439

844-PET-VIVO (738-8486)

www.petvivo.com

info1@petvivo.com

Spryng™ and OsteoCushion™ technology is a trademark of PetVivo Holdings Inc. This product is covered by U.S. Patent Nos. (US 8,153,591; US 9,107,937; US 9,999,705; US 10,850,006; US 11,890,371; US 11,975,121; CA 2,537,315; CA 2,583,561) and other pending applications and foreign patents. ©2024 PetVivo, Inc. All rights reserved.

TPD-19 Rev. 10-24

CPN: 2127000.2